Vir Biotechnology, Inc. (VIR)
NASDAQ:VIR
Want to see VIR full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.33Last Year’s EPS
-0.8Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed substantial positive momentum: a large strategic collaboration with Astellas closed with immediate and near-term cash, meaningful capital raises, strong Phase 1 safety/early efficacy for VIR-5500, and highly differentiated Phase 2 HDV data with regulatory support and multiple registrational trials underway. Offsetting these positives are continued quarterly net losses, high R&D spend, the need for multiple pivotal datasets for filing in HDV, underdiagnosis in the target HDV population, and class-level safety/competitive risks for T cell engagers. On balance, the advances in clinical data, strategic partnerships, and strengthened balance sheet materially outweigh the near-term financial and execution risks.Company Guidance
Strategic Astellas Collaboration Closed
Entered and closed a global collaboration and licensing agreement with Astellas for VIR-5500 valued up to $1.7 billion; Vir received $75 million equity at closing and will receive a $240 million upfront payment within 30 days (total $315 million in proceeds), is eligible for up to $1.37 billion in additional milestones, and will share U.S. commercial profit 50/50.
Material Capital Raises and Balance Sheet Strength
Completed a follow-on equity offering that generated approximately $172.5 million gross; ended Q1 2026 with ~$809.3 million in cash, cash equivalents and investments (excluding the $315M Astellas proceeds received after quarter-end); management expects cash runway into 2028.
VIR-5500 Phase 1 Safety and Early Efficacy
Phase 1 data for VIR-5500 showed favorable safety with no dose-limiting toxicities and mostly Grade 1 cytokine release syndrome at ≥3,000 µg/kg with no observed Grade 3 CRS at that dose; observed deep PSA and RECIST responses with sustained responses up to 27 weeks and case-level durability of 8–12 months, including a complete response in a patient who relapsed after actinium-based PSMA RLT.
Operational Progress in VIR-5500 Development
Dosed first patient in the Phase 1 expansion cohorts (monotherapy) and continuing dose escalation in combination with enzalutamide for early-line mCRPC; plan to initiate registrational Phase 3 program in 2027 pending data.
PROXTEN Platform Expansion and Pipeline Optionality
Advancing multiple PROXTEN-masked T cell engagers: VIR-5818 (HER2) is signal-seeking with planned preliminary response data in 2026, VIR-5525 (EGFR) enrollment progressing, plus seven preclinical PROXTEN assets to broaden pipeline optionality.
Compelling Hepatitis Delta (HDV) Phase 2 SOLSTICE Results
Tobevibart plus elebsiran combination showed strong viral suppression: 88% of evaluable participants achieved undetectable HDV RNA (TND) at Week 96 versus 46% on tobevibart monotherapy; rapid effect with 41% TND by Week 24 and 66% TND reported at Week 48 in pooled comments; combination was well tolerated with no Grade ≥3 treatment-related AEs and no discontinuations.
Regulatory Recognition and Clinical Program Momentum in HDV
Hepatitis delta regimen has FDA Breakthrough Therapy and Fast Track designations and EMA PRIME and orphan drug designation; ECLIPSE 1 enrollment complete (~120 randomized 2:1) with topline expected in Q4 2026, ECLIPSE 2 (~150) and ECLIPSE 3 (~100) on track to generate additional pivotal/registrational data.
Commercial Partnerships to Support Global Reach
Established commercialization partner Norgine with exclusive license across Europe, Australia and New Zealand for HDV; Astellas partnership adds global prostate cancer reach and shared development/commercial capabilities.
Year-over-Year Operating Expense Improvement
Total operating expenses for Q1 2026 were $132.3 million, a decrease of $10.3 million (≈7.2%) versus Q1 2025, driven by lower R&D and slightly lower SG&A.
VIR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
VIR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $10.29 | $9.27 | -9.91% |
Feb 23, 2026 | $7.43 | $9.49 | +27.73% |
Nov 05, 2025 | $5.40 | $5.12 | -5.19% |
Aug 06, 2025 | $5.08 | $4.35 | -14.37% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Vir Biotechnology, Inc. (VIR) report earnings?
Vir Biotechnology, Inc. (VIR) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is Vir Biotechnology, Inc. (VIR) earnings time?
Vir Biotechnology, Inc. (VIR) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is VIR EPS forecast?
VIR EPS forecast for the fiscal quarter 2026 (Q2) is 0.33.